Cargando…
A software tool for both the maximum tolerated dose and the optimal biological dose finding trials in early phase designs
BACKGROUND: Phase I and/or I/II oncology trials are conducted to find the maximum tolerated dose (MTD) and/or optimal biological dose (OBD) of a new drug or treatment. In these trials, for cytotoxic agents, the primary aim of the single-agent or drug-combination is to find the MTD with a certain tar...
Autores principales: | Li, Chen, Sun, Hongying, Cheng, Cheng, Tang, Li, Pan, Haitao |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9529556/ https://www.ncbi.nlm.nih.gov/pubmed/36203850 http://dx.doi.org/10.1016/j.conctc.2022.100990 |
Ejemplares similares
-
Bayesian optimization for estimating the maximum tolerated dose in Phase I clinical trials
por: Takahashi, Ami, et al.
Publicado: (2021) -
Adaptive design for identifying maximum tolerated dose early to accelerate dose-finding trial
por: Kojima, Masahiro
Publicado: (2022) -
Dose Titration Algorithm Tuning (DTAT) should supersede ‘the’ Maximum Tolerated Dose (MTD) in oncology dose-finding trials
por: Norris, David C.
Publicado: (2017) -
Pulmonary carcinogenicity of inhaled particles and the maximum tolerated dose.
por: Oberdörster, G
Publicado: (1997) -
Determination of maximum tolerated dose and toxicity of Inauhzin in mice
por: Zhang, Qi, et al.
Publicado: (2015)